Discover
AGMB
AgomAb Therapeutics NV
11.87
2 x 9.34
2 x 15.29
bid
ask
-
1.11
8.55%
2 @ 04:00 PM
12.03 +0.16 (1.35%)
| Ytd | -18.98% | |
| 1y | -18.98% |
11.53
day range
13.25
8.75
52 week range
17.82
| Open | 12.98 | Prev Close | 12.98 | Low | 11.53 | High | 13.25 | Mkt Cap | 584.57M |
| Vol | 166.65K | Avg Vol | 125.26K | EPS | -1.46 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 11.39 | 200-d Avg | 12.34 | 1yr Est | 0.00 |
AGMB News
benzinga.com
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phas
benzinga.com
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
benzinga.com
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mond
Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what a
benzinga.com
HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Targe
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NA